These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Miner P; Hanauer S; Robinson M; Schwartz J; Arora S Dig Dis Sci; 1995 Feb; 40(2):296-304. PubMed ID: 7851193 [TBL] [Abstract][Full Text] [Related]
5. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086 [TBL] [Abstract][Full Text] [Related]
6. Pentasa in maintenance treatment of ulcerative colitis. Gionchetti P; Campieri M; Belluzzi A; Brignola C; Tampieri M; Iannone P; Miglioli M; Barbara L Gastroenterology; 1990 Jan; 98(1):251. PubMed ID: 2293593 [No Abstract] [Full Text] [Related]
7. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Segars LW; Gales BJ Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685 [TBL] [Abstract][Full Text] [Related]
12. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Bondesen S; Rasmussen SN; Rask-Madsen J; Nielsen OH; Lauritsen K; Binder V; Hansen SH; Hvidberg EF Acta Med Scand; 1987; 221(3):227-42. PubMed ID: 3296672 [No Abstract] [Full Text] [Related]
13. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193 [TBL] [Abstract][Full Text] [Related]
14. Oral mesalamine for ulcerative colitis. Med Lett Drugs Ther; 1992 Aug; 34(877):80-1. PubMed ID: 1353858 [No Abstract] [Full Text] [Related]
15. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Mulder CJ; Tytgat GN; Weterman IT; Dekker W; Blok P; Schrijver M; van der Heide H Gastroenterology; 1988 Dec; 95(6):1449-53. PubMed ID: 2903110 [TBL] [Abstract][Full Text] [Related]
16. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889 [TBL] [Abstract][Full Text] [Related]
17. [Aminosalicylates in the treatment of chronic inflammatory bowel diseases]. Hartmann F; Plauth M Internist (Berl); 1990 Nov; 31(11):702-6. PubMed ID: 2289856 [No Abstract] [Full Text] [Related]
18. Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis. Drug Ther Bull; 1992 Jun; 30(13):50-2. PubMed ID: 1628539 [No Abstract] [Full Text] [Related]
19. [Exanthema in 2 patients with ulcerative colitis treated with Pentasa]. Grøn I; Winther A Ugeskr Laeger; 1988 Jan; 150(1):32. PubMed ID: 2967564 [No Abstract] [Full Text] [Related]
20. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Small RE; Schraa CC Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]